fibromyoma of uterus. Leiomyoma of uterus
Conditions
Interventions
Intervention 1: Intervention group:prescription of weekly 0.5 mg cabergoline for 3 months. Intervention 2: Control group: monitoring without drug prescription for 3 months.
Treatment - Drugs
Intervention group:prescription of weekly 0.5 mg cabergoline for 3 months.
Control group: monitoring without drug prescription for 3 months.
Sponsors
Vice chancellor for research ,Iran University of Medical Sciences.
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: symptomatic myoma including abnormal uterine bleeding ( after excluding the other etiologies), pelvic pain, and myoma in ultrasound with a minimum size of 2 centimeters. Exclusion criteria : severe bleeding; pregnancy; breast feeding; using any hormone or sedative; any other pathology in ultrasound; any known hormonal problems and any conditions need to an emergency treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the size of myoma. Timepoint: 3 months after treatment. Method of measurement: Ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of the symptoms including pelvic pain and amount of bleeding. Timepoint: 3 months after treatment. Method of measurement: Questionair and VAS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Kashanian
Iran University of Medical Sciences
Outcome results
None listed